Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.…
Inventiva (IVA) vs. CRSP and MDGL: Can Lanifibranor’s Phase 3 Trial Unlock 62% Upside?
Inventiva (NASDAQ: IVA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 87 employees.
The shares were at 3.140 USD on 20 November 2026, down 22.5% over 52 weeks. Its 52-week range is 2.820 USD to 7.290 USD: the price is 56.9% below the high and 11.3% above the low.
Its market capitalisation is 750.78M USD.
Inventiva reports revenue down 76.7% year over year.
It holds more cash than debt, a net cash position of 27.34M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 1 April 2027.